Functional ability and muscle force in healthy children and ambulant Duchenne muscular dystrophy patients

• Published in: European journal of paediatric neurology Vol. 9; no. 6; pp. 387 - 393
• Main Authors: Beenakker, Ernesto A.C., Maurits, Natalia M., Fock, Johanna M., Brouwer, Oebele F., van der Hoeven, Johannes H.
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01-01-2005
• Subjects: Aging - physiology; Ankle - physiology; Body Mass Index; Child; Child, Preschool; Children; Disease Progression; Duchenne muscular dystrophy; Female; Functional Laterality - physiology; Humans; Male; Muscle force; Muscle, Skeletal - physiopathology; Muscular Dystrophy, Duchenne - physiopathology; Reference Values; Running; Timed tests; Timed tests; Children; Muscle force; Duchenne muscular dystrophy
• ISSN: 1090-3798; 1532-2130
• DOI: 10.1016/j.ejpn.2005.06.004

Neuromuscular disorders are characterised by progressive muscle weakness, which in time causes functional impairment. To quantify the extent of disease progression, muscle force and functional ability can be measured. Which of these parameters changes most depends on the disease stage.
In a previous study, we reported normal values for muscle force obtained by hand-held dynamometry in healthy children aged 4–16 years. In the present study, we report normal values for timed functional tests in healthy children aged 4–11 years.
These normal values were compared with values obtained in 16 ambulant patients with Duchenne muscular dystrophy (DMD) aged 5–8 years to study the extent of functional impairment.
In ambulant patients with DMD, we found that muscle function assessed by timed functional tests (running 9
m and rising up from the floor) and muscle force assessed by hand-held dynamometry were severely impaired. However, a small reduction of muscle force was accompanied by a large reduction in functional ability. Therefore, in our group of ambulant patients with DMD, timed functional testing was the most sensitive parameter to determine the extent of disease progression. Timed functional testing may therefore be considered as an additional outcome measure in drug trials to evaluate the effects of therapy in ambulant patients with DMD and possibly in other neuromuscular disorders.